Biodexa Pharmaceuticals (BDRX) FCF Margin (2015 - 2021)

Biodexa Pharmaceuticals (BDRX) has 5 years of FCF Margin data on file, last reported at 47.13% in Q4 2021.

• For the quarter ending Q4 2021, FCF Margin rose 8753463.0% year-over-year to 47.13%; the trailing twelve-month figure through Dec 2021 stood at 1522.1% (up 34484.0% YoY), and the FY2023 full-year result was 1784.78%, down 78535.0% from the prior year.
• FCF Margin advanced to 47.13% in Q4 2021, from 87487.5% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 47.13% in Q4 2021 to a low of 87487.5% in Q3 2020.
• A 3-year average of 44225.55% and a median of 44730.92% in 2019 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin sank 8551315 bps in 2020 and surged 8753463 bps in 2021, its largest moves.
• Tracing BDRX's FCF Margin over 3 years: stood at 1974.35% in 2019, then slumped by 4331 bps to 87487.5% in 2020, then soared by 100 bps to 47.13% in 2021.
• Business Quant data shows BDRX's FCF Margin at 47.13% in Q4 2021, 87487.5% in Q4 2020, and 87487.5% in Q3 2020.